Mednet Logo
CommunityEndocrinology

What factors would lead you to extend the duration of antithyroid drug therapy in a patient with Graves' disease who is clinically euthyroid at 12 months but has risk factors for recurrence?

Community PollStarted

What factors help you decide the duration of antithyroid drug therapy in a patient with Graves' disease who is clinically euthyroid?

60 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet MemberInvited Expert
Endocrinology · Johns Hopkins Outpatient Endocrinology
Answered on

One should never discontinue methimazole after an arbitrary period of time without checking anti-TSH receptor antibody levels. If they are positive or even “normal” but not undetectable, the patient will inevitably have a recurrence of their hyperthyroidism relatively quickly (Laurberg et al., PMID ...

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Endocrinology · Access Endocrinology Llc
Answered on

Agree with Dr. @Dr. First Last. The patients rely on our guidance for ATD, versus RAI, and rarely surgery. It is expensive for some patients to continue to have visits and tft's several times a year on ATD, compared to patients who may have post-ablative hypothyroid on stable thyroxine treatment who...

Join for free or sign in to see the full answer

Join for free or sign in to see the full answer